IL13 and primary cutaneous T-cell non-Hodgkin lymphoma: Moreover, blocking IL-13—alone or in conjunction with IL-4—may restore antitumor immunity in the local microenvironment by lessening Th2 skewing which is associated with immune escape in CTCL [55].